Trial Profile
A small phase 3 trial of Leronlimab in critically ill Covid 19 patients
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- 30 Mar 2022 According to an CytoDyn media release, Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting
- 30 Mar 2022 Status changed from recruiting to suspended, according to an CytoDyn media release.
- 08 Dec 2021 According to a CytoDyn media release, CytoDyn will submit the revised protocol for CD16 providing for a reduction in total enrollment from 330 to 126 patients, with interim efficacy analysis by DSMB after 40% of patients (51 patients) are enrolled and have completed follow-up to Day 28 (potentially in 1Q2022)